Ocular gene therapy for neovascular AMD: a new era? - Authors' reply

Affiliations

¹ Departments of Ophthalmology and Neuroscience, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287-9277, USA. Electronic address: pcampo@jhmi.edu.
² Ophthalmic Consultants of Boston, Boston, MA, USA.
³ Departments of Ophthalmology and Neuroscience, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287-9277, USA.
⁴ Sanofi Genzyme, Cambridge, MA, USA.
⁵ Casebia Therapeutics LLC, Cambridge, MA, USA.

Comment

Peter A Campochiaro et al. Lancet. 2017.

. 2017 Nov 11;390(10108):2140.

doi: 10.1016/S0140-6736(17)32424-8. Epub 2017 Nov 9.

¹ Departments of Ophthalmology and Neuroscience, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287-9277, USA. Electronic address: pcampo@jhmi.edu.
² Ophthalmic Consultants of Boston, Boston, MA, USA.
³ Departments of Ophthalmology and Neuroscience, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287-9277, USA.
⁴ Sanofi Genzyme, Cambridge, MA, USA.
⁵ Casebia Therapeutics LLC, Cambridge, MA, USA.

No abstract available

Comment on

Ocular gene therapy for neovascular AMD: a new era?
Chatziralli IP, Sergentanis TN. Chatziralli IP, et al. Lancet. 2017 Nov 11;390(10108):2139-2140. doi: 10.1016/S0140-6736(17)32447-9. Epub 2017 Nov 9. Lancet. 2017. PMID: 29143749 No abstract available.